Keeping pace with the ever-evolving landscape of health care enforcement can prove challenging. In the latest EnforceMintz newsletter, Mintz’s Health Care Enforcement Defense practice group highlights emerging enforcement trends, developments in FCA investigations, and provides predictions for 2024, offering helpful guidance through the complexities of health care enforcement.
Mintz has been recognized as one of the “2024 Best Companies to Work For” by the US News & World Report. The recognition is based on six critical factors: quality of pay, work life balance, stability, comfort, belongingness, and professional development. Our ratings reflect Mintz’s dedication to fostering a workplace culture that values professional growth, work-life balance, and overall employee well-being.
Reverse mergers aren’t an alternative to an IPO, rather they can be a strategic approach for companies looking to go public by leveraging “fallen angels”. Mintz Members Bill Hicks and John Rudy answer frequently asked questions for private companies considering a reverse merger in an article featured in PitchBook’s 2023 Annual US VC Valuations Report. The authors detail the benefits and challenges associated with a reverse merger including finding partners, PIPE financing, Nasdaq access for non-US companies, and SEC implications.
The Cigna Health Group signed a deal selling its Medicare businesses to Health Care Service Corporation (HCSC) for $3.7 billion. A Mintz team led by Tara Dwyer and Lauren Moldawer acted as regulatory counsel to The Cigna Group on the sale. In the deal, which is expected to close in the first quarter of 2025, HCSC will acquire Cigna’s Medicare lines including Medicare Advantage, Medicare supplement, and Medicare drug plans, as well as CareAllies, a unit that works with physician groups and other healthcare providers.
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
As the spotlight intensifies on AI, the discourse around regulation will take center stage in 2024. In a recent article featured in the New York Law Journal, Member Jason Halperin and Associates Edmund Daley and Elizabeth Platonova navigate the intricacies of AI development and safety. Their comprehensive analysis includes a review of President Biden’s October 30 executive order for AI and an exploration of ongoing regulatory efforts in the US and EU, and what companies need to do to navigate them.
Awards and Recognition
Best Law Firms 2024
Ranked by Best Lawyers
The firm received 69 top-tier national and regional rankings in the 2024 edition.
AmLaw 100 2023
Mintz ranks among the top 100 US law firms in terms of gross revenue.
The 2023 edition recognized 81 Mintz attorneys and 39 of the firm’s practices as leaders in their fields.
Human Rights Campaign Foundation 2023
Equality 100 Leader in LGBTQ+ Workplace Inclusion
Mintz received its 16th consecutive perfect score on the Human Rights Campaign Foundation's Corporate Equality Index